DEXCHLORPHENIRAMINE
Sponsors
Assistance Publique Hopitaux De Paris, Fundacion Publica Andaluza para la Gestion de la Investigacion en Salud de Sevilla (FISEVI), Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La Ciencia, Sanofi-Aventis Recherche & Developpement, Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Conditions
ANCA-associated vasculitisAcute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myelodysplastic syndrome - Blastic plasmacytoid dendritic cell neoplasiaAcute lymphoid leukemiaMultiple SclerosisMultiple myeloma.Post COVID-19Progressive Multiple SclerosisViral Infections of the Upper Respiratory Tract
Phase 1
A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
CompletedNCT02583594
Start: 2015-12-06End: 2021-03-01Updated: 2021-03-10
An open-label, first-in-human, dose-escalation/expansion study of SAR443579 administered as single agent by intravenous infusion in adult and pediatric participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)
CompletedCTIS2023-508357-58-00
Start: 2022-07-04End: 2025-03-12Target: 57Updated: 2025-06-23
Anti-BCMA chimeric antigen receptor (CARTemis-1) T-lymphocyte therapy
in the treatment of patients with multiple myeloma in relapse after
allogeneic transplant: EGFR expression as a control mechanism of
treatment-derived complications
RecruitingCTIS2022-503063-15-00
Start: 2025-09-22Target: 25Updated: 2025-01-17
Phase 2
Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z (ARI-0001 cells) in patients with CD19+ acute lymphoid leukemia resistant or refractory to therapy
Not yet recruitingCTIS2024-513601-31-00
Target: 32Updated: 2024-10-24
Phase II proof-of-concept, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of plitidepsin in adults with post-COVID-19 Condition (PCC)
RecruitingCTIS2024-516378-31-00
Start: 2025-02-07Target: 90Updated: 2025-07-31
Phase 3
Comparison Between Dexchlorpheniramine and Dexchlorpheniramine/Pseudoephedrine/Guaifenesin in Respiratory Infections
NCT01085721
Target: 170Updated: 2010-03-12
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
TerminatedNCT03368664
Start: 2017-10-24End: 2025-09-08Updated: 2025-11-26
A multicenter randomized trial to evaluate the efficacy of pioglitazone to promote renal tolerance in ANCA-associated vasculitis - RENATO
RecruitingCTIS2022-501057-36-00
Start: 2023-10-24Target: 126Updated: 2026-01-26
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post COVID-19 Condition
WithdrawnCTIS2023-504087-42-00
Target: 260Updated: 2023-08-10